Hugel Posts 105.9 Billion Won in Q3 Sales... Surpasses 100 Billion Won for Second Consecutive Quarter

Operating Profit of 47.4 Billion Won, Net Profit of 38 Billion Won

Hugel announced on November 4 that, based on its consolidated financial statements, it recorded sales of 105.9 billion won, operating profit of 47.4 billion won, and net profit of 38 billion won in the third quarter of this year. The gross profit margin reached 77%, while the operating margin was 45%.

Hugel

The export share of combined sales from toxin and filler products reached 80%, with overseas sales of these two items in the third quarter rising by over 11% year-on-year to 72.6 billion won. Among these, the global Big Four markets (the United States, China, Europe, and Brazil) accounted for about 45% of total sales, serving as a major driver of performance.

Breaking down third-quarter sales by product, toxin (Botulax) recorded 60.2 billion won, and fillers (The Chaeum and Bioregen) accounted for 30.2 billion won. Cosmetics (Wellage and Bioregen BR) posted 14.9 billion won, up 65% from the same period last year.

Hugel Global CEO Carrie Strom stated, "It is very encouraging that we are continuing to see sales growth and expanding market share, particularly in the Big Four regions-the United States, China, Europe, and Brazil-which represent 80% of the global toxin market."

Hugel Korea CEO Jang Dohyun said, "Starting from the third quarter, we have been focusing on holding academic seminars for medical professionals both domestically and internationally, as well as marketing activities targeting consumers. With our corporate and product competitiveness and having achieved sales of over 100 billion won for two consecutive quarters, we will further solidify our competitive edge in the market."

This content was produced with the assistance of AI translation services.